Levee Medical: Improving Recovery for Men After Prostate Cancer Surgery
A prostate cancer diagnosis forces men to brace for a difficult medical journey. What many do not expect is the challenging recovery that can follow surgery itself. Radical prostatectomy can cure cancer, yet it often leaves patients facing urinary incontinence during the first weeks or months, and sometimes far longer. These complications can affect confidence, mobility, and daily life in ways patients rarely anticipate.
Levee Medical was created to improve that experience.
The Problem
Prostate cancer is the most common cancer diagnosis among men in the United States other than skin cancer, and it is the second leading cause of cancer death in men. Many patients with localized disease are treated with radical prostatectomy. The procedure can remove the cancer, but the return of urinary control is slow for many and incomplete for a meaningful number of men. The result is a recovery period marked by uncertainty, frustration, and loss of independence.
Levee Medical, headquartered in Durham, North Carolina, focuses on designing solutions that reduce complications following prostate cancer surgery. Their goal is to help patients recover more predictably and return to their lives with greater confidence.
The Innovation
Levee’s lead technology is the Voro Urologic Scaffold. It is a bioabsorbable implant that is placed during robotic-assisted radical prostatectomy. The device is designed to support the bladder neck and preserve urethral length during healing. These two anatomical factors play important roles in the recovery of continence after surgery. As healing progresses, the scaffold gradually dissolves and the body remodels the area naturally. The intention is to create better early support at the surgical site and a smoother path to continence for patients. Voro is an investigational device and is not approved for commercial use in any country.
Levee has moved steadily from early development into pivotal clinical evaluation.
In 2022, the company closed a $6.6 million oversubscribed Series A round to advance development of the Voro scaffold.
In 2023, Levee received a $4.3 million investment to accelerate clinical work.
In February 2025, the company announced a $10 million oversubscribed Series B financing, bringing total Series B-related proceeds to more than $15 million once note conversions were included. These funds support ongoing clinical studies and continued development of the Voro scaffold.
In March 2025, the United States Food and Drug Administration granted an Investigational Device Exemption that allowed Levee to initiate the ARID II pivotal trial.
On April 24, 2025, the first patient was enrolled in ARID II, which is designed to include up to 266 participants at as many as 30 centers in the United States.
In September 2025, Levee announced the issuance of a foundational United States patent covering key features of the Voro Urologic Scaffold.
In October 2025, the American Medical Association approved a Category III CPT add-on code for placement of the Voro scaffold during radical prostatectomy. Category III codes support data collection and signal formal recognition of a developing procedure, although Voro remains investigational.
These milestones show a company that is executing effectively and building a strong clinical, regulatory, and intellectual property foundation.
Why it Matters
For patients, the possibility of regaining urinary control sooner can change the entire recovery experience. Many men describe postoperative incontinence as more disruptive than the cancer surgery itself. A device that provides early structural support at the surgical site has the potential to reduce these challenges and restore quality of life more quickly and more reliably.
For surgeons and health systems, the ability to improve continence outcomes at the point of surgery could define a new standard of care. A solution that integrates directly into an existing surgical workflow and reduces downstream complications can create meaningful clinical and operational benefits.
Our Support
Fourscore has continued to support Levee in several key areas including serving as outside general counsel handling all corporate legal work and advising the Company through each round of financing from its first convertible note financing through its Series B financing round.
Looking Ahead
Levee Medical is entering an important chapter as the ARID II pivotal trial advances and the company continues to strengthen its clinical and regulatory platform. The Voro scaffold represents a novel approach to supporting continence after prostate cancer surgery. If the pivotal data confirm early feasibility findings, Voro has the potential to create a new category of postoperative support and to significantly improve the way patients recover from radical prostatectomy.
Fourscore Business Law is proud to support Levee’s work and the patients who stand to benefit from it.
To learn more about Levee Medical, visit Leveemedical.com.
To learn more about Fourscore’s legal services for business owners and founders, visit fourscorelaw.com.
Picture on the top is by National Cancer Institute and is in the public domain.